Good afternoon sir- yes, it’s completely situational.
Several catalysts to consider but for sake of ease, I’m in agreement with your price. If there was a catalyst that could move it higher, I would adjust. I think Covid has lent itself to some revisionist history by some (not you)
BLA was already baked into the price at $1.50 after the Vyera deal. However with Covid playing interference we didn’t focus on BLA. Now that CV19 is losing its luster and BLA/EUA and uplist are DOA, the sins of the past are rearing their ugly heads.
BLA is no longer a price mover in my opinion. I’ve been critical of Nader and rightfully so. I honestly think the beginning of end is approaching for him. The BOD have illusions of grandeur with their stock allocations and as they sink too low, those plans go up in smoke. There’s an old saying: there’s no honor among thieves. They’re all enriching themselves with shares but they’re no good if they’re worth 1/4 of what they should be. At some point they’ll come to the conclusion that Nader is in over his head, full of shit and we are two years behind where we should be...which would be HIV combo generating revenue to fund operations, have the confidence of the FDA and get the Vyera milestone payments.
Soooooo, to answer the question specifically I would say that $1.50-1.75 would be enough for me to take a strong position IF the chances of a change were increasing and the risk of bankruptcy wasn’t there.
We have no revenue and a large monthly burn rate, coupled with payments to Samsung for product and manufacturing.
This could get bumpy. Hope that answers your question.
Best to you! I pray your patience and diligence pays off
Grip
News 
Market Data 
Discover 
